Unknown

Dataset Information

0

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.


ABSTRACT: BACKGROUND:Anti-drug antibodies (ADAs) to bococizumab were detected in?>?40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kexin type-9 (PCSK9) monoclonal antibodies (mAbs) was investigated using a single-assay approach. METHODS:Bococizumab immunogenicity was assessed in SPIRE-HR, a 52-week study. The highest ADA titer sample from each ADA-positive subject (n?=?155) was tested in vitro for cross-reactivity to alirocumab and evolocumab using a novel ADA assay approach. Additional specificity tiers within the bococizumab ADA assay against each drug were validated using recombinant PCSK9 as a surrogate cross-reactive positive control. If the highest ADA titer sample showed cross-reactivity, additional samples from that subject were analyzed. Cross-reactivity was determined by the ability of alirocumab or evolocumab to inhibit the sample signal greater than or equal to the cross-reactivity cut-points. RESULTS:ADAs were detected in 44.0% (155/352) of bococizumab-treated subjects, and 27.0% also developed neutralizing antibodies (NAbs). Median ADA and NAb titers ranged from 276 to 526 and 8 to 12 over the course of the study, respectively. From 155 ADA-positive subjects tested for cross-reactivity, one (0.6%) subject showed weak cross-reactivity to both alirocumab and evolocumab. This cross-reactivity signal was transient (from Days 337 to 373) and undetectable at the last ADA-positive timepoint (Day 407). CONCLUSION:A novel, single-assay approach was validated to assess the potential cross-reactivity of anti-bococizumab antibodies to alirocumab and evolocumab. In subjects who developed ADAs to bococizumab, the likelihood of clinically relevant cross-reactivity to marketed anti-PCSK9 mAbs is remote, based on the low frequency of cross-reactivity observed, which was weak in signal inhibition and transient in nature. CLINICAL TRIAL REGISTRATION:The SPIRE-HR study is registered on ClinicalTrials.gov under the identifier NCT01968954.

SUBMITTER: Wang EQ 

PROVIDER: S-EPMC6790354 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.

Wang Ellen Q EQ   Bukowski Jack F JF   Yunis Carla C   Shear Charles L CL   Ridker Paul M PM   Schwartz Pamela F PF   Baltrukonis Daniel D  

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20191001 5


<h4>Background</h4>Anti-drug antibodies (ADAs) to bococizumab were detected in > 40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kexin type-9 (PCSK9) monoclonal antibodies (mAbs) was investigated using a single-assay approach.<h4>Methods</h4>Bococizumab immunogenicity was assessed in SPIRE-HR, a 52-week study. The highest ADA titer sample from each ADA-positive subject (n  ...[more]

Similar Datasets

| S-EPMC6862531 | biostudies-literature
| S-EPMC10725275 | biostudies-literature
| S-EPMC5886380 | biostudies-literature
| S-EPMC10330718 | biostudies-literature
| S-EPMC5099564 | biostudies-literature
| S-EPMC9267174 | biostudies-literature
| S-EPMC3572902 | biostudies-literature
| S-EPMC5499374 | biostudies-literature
| S-EPMC6698821 | biostudies-literature
| S-EPMC6478267 | biostudies-literature